Details of the Drug

General Information of Drug (ID: DM772MW)

Drug Name

Fazirsiran

Indication

Disease Entry	ICD 11	Status	REF
Alpha-1 antitrypsin deficiency	5C5A	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

RNA interference

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SERPINA1 messenger RNA (SERPINA1 mRNA)	TT2L4TV	A1AT_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05677971) A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis. U.S.National Institutes of Health.
2	Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524.